Alexion Pharmaceuticals, Inc.

Marc Vallee

Xiang Gao

Rajendra Pradhan

Douglas L Sheridan

Andrew Evan Denker

Stephan Ortiz

Lori Payton

Kenji Fujita

Dawn Phillips

Eugene Scott Swenson

Christian Mix

Lori Volles

Provided are methods for clinical treatment of Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof, in pediatric patients.

Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients

Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule). In one embodiment, the patient has previously been treated with eculizumab (Soliris®).

Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)

Growing community of inventors

Lexington, MA, United States of America

Marc Vallee